報價延遲最少15分鐘:2025/03/28 08:24 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
18.71 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-8.73/-2.20
|
|
企業價值
34.68M
|
| 資產負債 |
|
每股賬面淨值
3.96
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/03/28 08:24 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation. |